Novelion Therapeutics Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference
January 04, 2017 09:20 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, B.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with...
Novelion Therapeutics’ Subsidiary Files for European Approval for Metreleptin as a treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy
December 22, 2016 07:00 ET
|
Novelion Therapeutics, Inc.
- If approved, metreleptin would be the first medication available in the EU to treat generalized and partial lipodystrophies - More than 100 patients are currently treated with metreleptin via a...
Novelion Therapeutics Completes Reverse Stock Split
December 16, 2016 17:00 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for...
Novelion Therapeutics’ Subsidiary Launches JUXTAPID® (lomitapide) in Japan
December 16, 2016 08:35 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Novelion Therapeutics (NASDAQ:NVLN) (TSX:NVLN), today announced that subsidiary Aegerion Pharmaceuticals completed the first...
Aegerion Pharmaceuticals, a Subsidiary of Novelion Therapeutics, Enters into Agreement in Principle to Settle Class Action Shareholder Lawsuit
December 05, 2016 08:30 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care...
Novelion Therapeutics Subsidiary, Aegerion Pharmaceuticals, Enters Into Licensing Agreement With Amryt Pharma for LOJUXTA® (lomitapide)
December 05, 2016 02:00 ET
|
Novelion Therapeutics, Inc.
-- Transaction provides new royalty and potential milestone revenues, opportunity to reduce cost structure, and continuity of patient access to lomitapide – CAMBRIDGE, Mass., Dec. 05,...